Advertisement

Advertisement

2016 ASH Annual Meeting & Exposition

Hematologic Malignancies

Pacritinib Reduces Spleen Volume in Myelofibrosis

The investigational drug pacritinib met the primary endpoint of the phase III PERSIST-2 trial in high-risk patients with myelofibrosis and thrombocytopenia. Treatment with the Janus kinase (JAK)1/2 in...

leukemia

Martin Schrappe, MD, on Childhood ALL: Study Results on Reducing Treatment Burden (German Language Version)

Martin Schrappe, MD, of Christian-Albrechts University Kiel, discusses in German study findings on reduced intensity delayed intensification in standard-risk patients defined by minimal residual disea...

lymphoma

Robert E. Marcus, MD, on Follicular Lymphoma: Results From the GALLIUM Trial

Robert E. Marcus, MD, of Kings College Hospital, discusses study findings on obinutuzumab-based induction and maintenance in patients with previously untreated disease (Abstract 6).

leukemia

Julie Vose, MD, MBA, and Anjali Advani, MD, on AML: Results of Two Trials on Vadastuximab Talirine

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Anjali Advani, MD, of the Cleveland Clinic, discuss study findings on vadastuximab talirine as monotherapy and, in another trial,...

leukemia

Julie Vose, MD, MBA, and Mhairi Copland, MB, ChB, PhD, on CML: Data From the British DESTINY Study

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Mhairi Copland, MB, ChB, PhD, of the Paul O’Gorman Leukaemia Research Centre at the University of Glasgow, discuss decreasing the...

leukemia

Harry P. Erba, MD, PhD, on AML: Early Study Results on Vadastuximab Talirine

Harry P. Erba, MD, PhD, of the University of Alabama at Birmingham, discusses phase Ib findings on vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed AML...

leukemia

Jeffrey E. Lancet, MD, on AML: Subgroup Analysis of a Phase III Trial

Jeffrey E. Lancet, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses study findings on survival following allogeneic hematopoietic cell transplantation in older, high-risk acut...

Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Results of the CheckMate 039 Trial

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses phase I study findings on nivolumab in combination with ipilimumab for relapsed or refractory disease (Abstract 183).

leukemia

Terry J. Fry, MD, on ALL: MRD and CAR Therapy

Terry J. Fry, MD, of the Pediatric Oncology Branch of the National Cancer Institute, discusses minimal residual disease–negative complete remissions following anti-CD22 chimeric antigen receptor in ch...

leukemia

Martin Schrappe, MD, on Childhood ALL: Study Results on Reducing Treatment Burden

Martin Schrappe, MD, of Christian-Albrechts University Kiel, discusses study findings on reduced intensity delayed intensification in standard-risk patients defined by minimal residual disease in chil...

lymphoma

Steven Le Gouill, MD, PhD, on Mantle Cell Lymphoma: Final Results From the LyMa Trial (French Language Version)

Steven Le Gouill, MD, PhD, of Nantes University Hospital and INSERM, discusses in French study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation ...

lymphoma

Catherine Thieblemont, MD, PhD, on DLBCL: Results From the Lysa Remarc Study (French Language Version)

Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, discusses in French phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the fi...

lymphoma

Steven Le Gouill, MD, PhD, on Mantle Cell Lymphoma: Final Results From the LyMa Trial

Steven Le Gouill, MD, PhD, of Nantes University Hospital and INSERM, discusses study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation in younger...

hematologic malignancies
issues in oncology

Marie Bleakley, MD, PhD, on GVHD: Reducing Rates and Increasing Survival

Marie Bleakley, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses data on using naive T-cell depletion of peripheral blood stem cells, which led to very low rates of chronic graft-vs-host-...

leukemia
survivorship

Smita Bhatia, MD, MPH, and Jessica Wu, BA, on CML: A Report From the Bone Marrow Transplant Survivor Study

Smita Bhatia, MD, MPH, and Jessica Wu, BA, both of the University of Alabama at Birmingham, discuss long-term morbidity and mortality experienced by chronic myeloid leukemia patients after allogeneic ...

leukemia

Syed A. Abutalib, MD, and Nelli Bejanyan, MD, on Adult ALL and Consolidation Chemotherapy: Results From a CIBMTR Study

Syed A. Abutalib, MD, of Cancer Treatment Centers of America, and Nelli Bejanyan, MD, of the University of Minnesota, discuss findings from a study conducted by the Center for International Blood and ...

lymphoma

Syed A. Abutalib, MD, and Alex F. Herrera, MD, on Double-Hit and Double-Expressor Lymphomas: A Retrospective Analysis

Syed A. Abutalib, MD, of Cancer Treatment Centers of America, and Alex F. Herrera, MD, of City of Hope National Medical Center, discuss study findings that suggest allogeneic stem cell transplantation...

lymphoma
geriatric oncology

Catherine Thieblemont, MD, PhD, and Julie Vose, MD, MBA, on DLBCL: Results From the Lysa Remarc Study

Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss phase III trial findings on lenalidomide maintenance i...

leukemia

Andrew D. Zelenetz, MD, on CLL: Emerging Treatments

Andrew D. Zelenetz, MD, of the Memorial Sloan Kettering Cancer Center, discusses novel treatments for chronic lymphocytic leukemia, touching specifically on the Gilead 115 trial.

lymphoma

Laurie H. Sehn, MD, MPH, on Follicular Lymphoma: Choosing the Best Target

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses agents in the pipeline for follicular lymphoma, including drugs targeting the immune microenvironment, novel monoclonal antibo...

lymphoma

Umberto Vitolo, MD, and Sagar Lonial, MD, on DLBCL: Final Results From the GOYA Trial

Umberto Vitolo, MD, of Città della Salute e della Scienza Hospital and University, and Sagar Lonial, MD, of Emory University, discuss study findings on obinutuzumab or rituximab plus CHOP in patients ...

hematologic malignancies
symptom management

Brenda M. Sandmaier, MD, and Sagar Lonial, MD, on Preventing GVHD: Clinical Trial Results

Brenda M. Sandmaier, MD, of Fred Hutchinson Cancer Research Center, and Sagar Lonial, MD, of Emory University, discuss study findings on sirolimus combined with mycophenolate mofetil and cyclosporine ...

leukemia

Jose F. Leis, MD, PhD, and Sagar Lonial, MD, on CLL: Ibrutinib Insights

Jose F. Leis, MD, PhD, of the Mayo Clinic, and Sagar Lonial, MD, of Emory University, discuss a session on CLL treatment (excluding transplantation): ibrutinib resistance, transformation, and cellular...

hematologic malignancies

Joshua Brody, MD, on Lymphoid Malignancies: Immunotherapy Update

Joshua Brody, MD, of the Icahn School of Medicine at Mount Sinai, summarizes important data on passive and active immunotherapy (Abstracts 1213, 1214, 1215, 1216, 1217, 1218).

hematologic malignancies
symptom management

Jean M. Connors, MD, and Julie Vose, MD, MBA, on Thrombosis and Anticoagulation: Best of ASH Clinical Data

Jean M. Connors, MD, of Brigham and Women’s Hospital, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss a roundup of key findings on a critical area in the treatment of he...

lymphoma

Jonathon Cohen, MD, and Sagar Lonial, MD, on DLBCL: Results of the CALGB/Alliance 50303 Trial

Jonathon Cohen, MD, and Sagar Lonial, MD, both of Emory University, discuss study findings on R-CHOP vs DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma (Abstract 469).

Advertisement

Advertisement



;
Advertisement